Log in

Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

$16.32
+0.27 (+1.68 %)
(As of 10/18/2019 04:43 AM ET)
Today's Range
$16.01
Now: $16.32
$16.33
50-Day Range
$13.97
MA: $15.62
$17.24
52-Week Range
$11.78
Now: $16.32
$23.91
Volume2.19 million shs
Average Volume7.63 million shs
Market Capitalization$5.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$0.40 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$5.83 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.01. The biopharmaceutical company had revenue of $100.40 million for the quarter, compared to analyst estimates of $99.54 million. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. Amarin's revenue was up 90.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

10 Wall Street analysts have issued 1 year price targets for Amarin's shares. Their predictions range from $17.00 to $51.00. On average, they anticipate Amarin's stock price to reach $29.20 in the next twelve months. This suggests a possible upside of 78.9% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (10/17/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on AMRN shares after the company reported its 2Q19 financials, which came in at the higher end of its 7/2 pre-announcement; however, the key update is the fact management announced it believes an adcom is unlikely for Vascepa’s sNDA now given the close proximity to its PDUFA date. As we have discussed in previous notes, we believed the lack of an adcom would further de-risk Vascepa’s sNDA – so we see this update as an incremental positive and gets us more confident in sNDA approval. Given the high probability of approval, we believe investor focus is shifting to: (1) how Vascepa’s expanded label will read; (2) commercial execution in 2020 given its planned sales force expansion and whether or not 2020 Vascepa consensus sales estimates are too low; and (3) the potential timing and outcomes of Vascepa’s ongoing ANDA litigation." (7/31/2019)

Has Amarin been receiving favorable news coverage?

Media headlines about AMRN stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Amarin.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), Canopy Growth (CGC), NVIDIA (NVDA), Square (SQ), Alibaba Group (BABA), Exelixis (EXEL), Bank of America (BAC), Gilead Sciences (GILD) and Novavax (NVAX).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

Who are Amarin's major shareholders?

Amarin's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.11%), First Midwest Bank Trust Division (0.04%), Ogorek Anthony Joseph NY ADV (0.01%), Wedbush Securities Inc. (0.00%), NEXT Financial Group Inc (0.00%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Wedbush Securities Inc., Valeo Financial Advisors LLC, Ogorek Anthony Joseph NY ADV and NEXT Financial Group Inc. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $16.32.

How big of a company is Amarin?

Amarin has a market capitalization of $5.83 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. View Additional Information About Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is Block C 77 Sir John Rogerson`s Quay Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  694 (Vote Outperform)
Underperform Votes:  419 (Vote Underperform)
Total Votes:  1,113
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel